NPPB and heart failure: This device has also been used in patients with heart failure (NYHA group III), with positive outcomes in 17 patients at the 12‐month follow‐up including improved quality of life, reduced NT‐proBNP, improved ejection fraction and exercise tolerance (Piayda et al., 2022).